Fig. 5: The effect of exosomal LGALS9 on the antigen presentation of DCs. | Cell Death & Disease

Fig. 5: The effect of exosomal LGALS9 on the antigen presentation of DCs.

From: Exosomal LGALS9 in the cerebrospinal fluid of glioblastoma patients suppressed dendritic cell antigen presentation and cytotoxic T-cell immunity

Fig. 5

a Western blot analysis of the expression of LGALS9 and CD63 in U87 MG LGALS9−/− cells and exosomes. b NTA of U87 MG LGALS9−/− and U87 MG WT Exos. c Flow cytometry detection of mCherry, HLA-A, CD40, TAP1 and LGALS9 in DCs exposed to designated U87 MG antigens and CFSE in T cells exposed to active DCs. d, e ELISA detection of the release of IFN-γ and granzyme B into cell culture medium by T cells exposed to DCs presenting designated U87 MG antigens. f The expression of LGALS9 and CD63 in GL-261 LGALS9−/− cells and exosomes. g NTA of the differences in particle sizes and counts in equal volumes of the cell culture medium of GL-261 LGALS9−/− and GL-261 wt cells. h–j CCK-8 detection of the proliferative activity of designated GL-261 cells. Tumor growth curves (k) and survival curves (l) of designated GL-261 tumor-bearing C57BL/6J mice. Tumor growth curves (m) and survival curves (n) of designated GL-261 tumor-bearing immunodeficient NOD-SCID mice. All data are shown as the mean ± SD; *p < 0.05 and **p < 0.01 by a t-test, each cell test was repeated three times, and the tumor-bearing mouse experiment were set up with 14 mice per group.

Back to article page